Precigen Confirms Nasdaq Global Select Market Listing
Ticker: PGEN · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1356090
| Field | Detail |
|---|---|
| Company | Precigen, Inc. (PGEN) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, corporate-governance, exchange-listing
TL;DR
**PGEN's stock remains listed on Nasdaq, business as usual.**
AI Summary
Precigen, Inc. (PGEN) filed an 8-K on January 8, 2024, to disclose that its common stock, with no par value, is registered on the Nasdaq Global Select Market under the trading symbol PGEN. This filing is a routine update, confirming the company's listing and compliance with SEC regulations. For investors, this means Precigen continues to meet the listing requirements of a major exchange, which can impact liquidity and investor confidence.
Why It Matters
This filing confirms Precigen's continued listing on a major exchange, which is crucial for the stock's liquidity and visibility to institutional and retail investors.
Risk Assessment
Risk Level: low — This is a routine administrative filing with no new material financial or operational information, indicating very low risk.
Analyst Insight
Investors should view this as a routine compliance filing that doesn't introduce new financial or operational data. It simply confirms the company's existing stock exchange listing, so no immediate action is warranted based solely on this filing.
Key Players & Entities
- PRECIGEN, INC. (company) — the registrant filing the 8-K
- Nasdaq Global Select Market (company) — the exchange where Precigen's common stock is registered
- PGEN (company) — the trading symbol for Precigen's common stock
- January 8, 2024 (date) — date of the earliest event reported in the 8-K
FAQ
What is the purpose of this 8-K filing by Precigen, Inc.?
The purpose of this 8-K filing by Precigen, Inc. is to report the date of the earliest event, January 8, 2024, and to confirm that its Common Stock, No Par Value, is registered on the Nasdaq Global Select Market under the trading symbol PGEN, as per Item 1.01 and 9.01 of the filing.
On which stock exchange is Precigen, Inc.'s common stock traded?
Precigen, Inc.'s common stock is traded on the Nasdaq Global Select Market, as explicitly stated in the 'Securities registered pursuant to 12(b) of the Act' section of the filing.
What is the trading symbol for Precigen, Inc.?
The trading symbol for Precigen, Inc. is PGEN, as indicated in the 'Trading Symbol(s)' column of the 'Securities registered pursuant to 12(b) of the Act' table within the filing.
What is the state of incorporation for Precigen, Inc.?
Precigen, Inc. is incorporated in Virginia, as stated under the 'State or other jurisdiction of incorporation' section of the filing.
What is the business address and phone number of Precigen, Inc.?
The business address of Precigen, Inc. is 20374 Seneca Meadows Parkway, Germantown, Maryland 20876, and its telephone number is (301) 556-9900, as provided in the filing's header information.
Filing Stats: 492 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-01-08 08:39:30
Filing Documents
- dp205018_8k.htm (8-K) — 23KB
- dp205018_ex9901.htm (EX-99.1) — 35KB
- image_001.jpg (GRAPHIC) — 2KB
- 0000950103-24-000379.txt ( ) — 235KB
- pgen-20240108.xsd (EX-101.SCH) — 3KB
- pgen-20240108_lab.xml (EX-101.LAB) — 33KB
- pgen-20240108_pre.xml (EX-101.PRE) — 22KB
- dp205018_8k_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure. On January 8, 2024, Precigen, Inc. (the "Company") issued a press release providing an overview of certain research and development and corporate updates that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. A copy of the press release is attached hereto as Exhibit 99.1. This information, including the Exhibit attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit 99.1 Press Release issued by Precigen, Inc., dated January 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Precigen, Inc. By: /s/ Donald P. Lehr Donald P. Lehr Chief Legal Officer Dated: January 8, 2024